Subsequent Event

9 Months Ended

Sep. 30, 2018

Subsequent Event

Subsequent Event

20.  Subsequent Event

On October 15, 2018, the Company acquired an 80% interest in Hain Lifescience GmbH (“Hain”), a privately held Company, for a purchase price of EUR 66 million (approximately $76.4 million), with an option to acquire the remaining 20% equity interest, which is exercisable in or after 2022. Hain is an infectious disease specialist with a broad range of molecular diagnostics solutions for the detection of microbial and viral pathogens, as well as for molecular antibiotic resistance testing.   Hain is located in Nehren, Germany and will be integrated into the Bruker CALID Group within the BSI Segment. The purchase accounting for this acquisition will be finalized within the measurement period.